Latest news

Preclinical Data for SRA737 in Ovarian Cancer

15 November 2018

AGM NOTICE

14 November 2018

Directorate Change

Michael Owen, Ph.D and Clive Birch appointed as Non-Executive Directors

13 November 2018

Sierra Oncology Q3 2018 Results

08 November 2018

Find out more

Partners

Sareum actively seeks collaboration partners for its research programmes.

Find out more large-arrow.png

Pipeline

Sareum has an innovative pipeline of drug development candidates.

Find out more large-arrow.png

Presentationssmall-arrow.png

Proactive Investors, March 2018 (Video)

  • @Sareumplc Latest tweet

    RT @sierraoncology: Sierra’s Chk1i SRA737 demonstrates robust preclinical efficacy in aggressive CCNE1- & MYCN- ovarian cancer PDX models;… via @Sareumplc
    View more